Navigation Links
Rigel Announces Presentations at Two Investor Conferences
Date:10/28/2009

SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, executive vice president and chief operating officer of Rigel, will present at two separate investor conferences in November. Details of each conference are as follows:

    Oppenheimer 20th Annual Healthcare Conference
    Waldorf Astoria, New York City, NY
    November 3, 2:10 p.m. EST
    Speaker: Raul R. Rodriguez

    Credit Suisse 18th Annual Healthcare Conference
    Arizona Biltmore Hotel, Phoenix, AZ
    November 11, 2:00 p.m. MST
    Speaker: James M. Gower

Both presentations will be webcast. To access the live webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

    Contact: Raul R. Rodriguez
    Phone: 650-624-1302
    Email: invrel@rigel.com

    Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
    Phone: 650.430.3777
    Email: susan@alchemyemail.com

SOURCE Rigel Pharmaceuticals, Inc.


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
2. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
3. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
4. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
5. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
6. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
7. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
8. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
9. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
10. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
11. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... -- While you may be familiar with watching a film or TV show in high definition, you ... in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s top ... http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... YORK , May 3, 2016 ... (MRI) Market Size, Share, Development, Growth and Demand Forecast ... Open), by Field Strength (High Field, Very High Field, ... Application (Brain, Head and Neck, Spine, Musculoskeletal, Vascular, Breast, ... the global magnetic resonance imaging (MRI) market was valued ...
(Date:5/3/2016)... 3, 2016 Global and ... a basic overview of the industry that covers ... surgical mesh report explores into the international and ... report on Surgical Mesh market spread across 150 ... and figures is available at http://www.reportsnreports.com/reports/470569-global-and-chinese-surgical-mesh-industry-2016-market-research-report.html ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Pigment Laser Tattoo Removal Center is ... of the new PiQo4™ laser, the first 4-wavelenth picosecond laser to receive FDA Clearance. ... other picosecond laser on the market. Jeremy Miller, Tattoo Artist and former reality ...
(Date:5/5/2016)... ... , ... Liposuction specialist Marcia V. Byrd, MD spoke last month at the ... St. Louis Airport Hotel. This year’s conference was titled “Living with Lipedema and Dealing ... specialization in treating Lipedema. Dr. Byrd is considered one of the leading physicians in ...
(Date:5/5/2016)... ... May 05, 2016 , ... In the midst of making plans ... most important arrangement — planning a safe way of getting home after the festivities. ... Unfortunately, these celebrations often lead to drunk drivers on the roads who become involved ...
(Date:5/5/2016)... ... May 05, 2016 , ... In an effort ... GrassrootsHealth, a public health promotion and research organization, declared May as “National Sunshine ... and other shifts in cultural behavior over the past several decades, Americans spend ...
(Date:5/5/2016)... ... 2016 , ... The Wisconsin Independent Private Practice Alliance (WIPPA/aka ... WCS, has been selected by the Wisconsin Physical Therapy Association (WPTA) as this ... is awarded annually to a member of the WPTA to recognize a Wisconsin ...
Breaking Medicine News(10 mins):